NCT05053971
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 99 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Site details revised at 3 of 3 sites
Notable Eligibility criteria shortened, about 12 words Show 4 more changesShow less
- Secondary endpoints: details revised at 3 of 4 entries
- Study description revised
- Site contacts updated at 1 of 3 sites
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027v96
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
PHASE I RUN-IN PERIOD (DAILY DOSING) (NO LONGER USED PER AMENDMENT DATED JUNE 12, 2025): Patients receive ZEN003694 PO QD during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy. PHASE I \& II COMBINATION TREATMENT (DAILY DOSING) (NO LONGER USED PER AMENDMENT DATED JUNE 12, 2025): Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14. PHASE I and PHASE II (INTERMITTENT DOSING): Patients receive entinostat PO on days 1, 8, 15, and 22 of each cycle and ZEN003694 PO QD on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT throughout the study.
Drugs: BET Bromodomain Inhibitor ZEN-3694, Entinostat
Procedures: Computed Tomography, Core Biopsy
Sites
3 sites in 1 country